Equity Brief · Healthcare2026-05-20
BAYN.DE·Healthcare

Bayer AG NA

I · KI-Analyse

Kurzfassung

Bayer makes prescription medicines for heart disease, women's health, cancer, and blood disorders; sells consumer brands like Midol and Aspirin; and provides seeds, pesticides, and digital farming tools to agriculture customers worldwide [Yahoo Finance]. The Crop Science division is the largest profit contributor, generating nearly half of total revenue [Simply Wall St].

Bayer is a 161-year-old German life sciences giant operating three major divisions: prescription drugs (Pharmaceuticals), over-the-counter health products (Consumer Health), and agricultural seeds and crop chemicals (Crop Science) [Yahoo Finance]. The company currently reports a €2.2 billion net loss on €45.6 billion in revenue, but recent news signals potential recovery through two FDA priority-review drugs in stroke prevention and lung cancer [Yahoo Finance]. Bayer also faces ongoing environmental liabilities, including a recent $133 million settlement for PCB contamination cleanup [Seeking Alpha].

Bayer is currently unprofitable with moderate debt levels, but maintains strong gross margins and positive free cash flow [Yahoo Finance].

Kurzfassung AI analysisKonfidenz 7/10

Sentinellis-Score

4.2/10

Moderate concerns

Marktkapitalisierung

EUR 37.8B

Umsatz (12 Monate)

EUR 45.6B

II · Aktuelle Nachrichten

Was den Kurs bewegt hat

6 stories · ranked by relevance

  • macro2026-05-20

    BAYRY or RHHBY: Which Is the Better Value Stock Right Now?

    Zacks

  • macro2026-05-20

    Should FDA Priority Review for HYRNUO’s First-Line Lung Cancer Use Require Action From Bayer (XTRA:BAYN) Investors?

    Yahoo Finance

  • macro2026-05-19

    Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention

    Yahoo Finance

  • macro2026-05-19

    Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

    Yahoo Finance

  • macro2026-05-19

    FDA Grants Priority Tag to Bayer's Oncology Drug for First-Line NSCLC

    Yahoo Finance

  • macro2026-05-17

    Assessing Bayer (XTRA:BAYN) Valuation After Mixed Share Performance And Profit Recovery Hopes

    Simply Wall St

Premium · kostenlos mit jedem Konto

Bayer reported a €2.2 billion net loss for the most recent fiscal year despite €45.6 billion in revenue, and the company remains unprofitable with a negative net margin of -7.9% [Yahoo Finance]

1 von 5 Risiken in diesem Bericht

Risiken

5

Chancen

5

Warnsignale

3

Führung

10

22 weitere Erkenntnisse im vollständigen Bericht — kostenlos mit jedem Konto.

Vollständige Bayer AG NA-Analyse freischalten

Erstellen Sie ein kostenloses Konto für den vollständigen KI-Bericht mit Quellenangaben im Text.

  • 5 Risiken, 5 Chancen und 3 Warnsignale — jeweils mit Quelle
  • Über 100 Finanzkennzahlen mit Charts und Vergleichen
  • Vollständige Nachrichten-Zusammenfassungen mit Quellenlinks
  • Führungsteam und Vergütung
  • PDF-Export für offline
Alle 13 Erkenntnisse freischalten3 kostenlose Berichte · keine Karte

III · Ähnliche Unternehmen

Das könnte Sie auch interessieren

Same sector · Healthcare or comparable health

Auf Ihre Watchlist setzen?

Read three companies free. Keine Karte.

3 kostenlose Berichte sichern
Bayer AG NA (BAYN.DE) Aktienanalyse in verständlicher Sprache — Sentinellis